Assessing the relevance and uptake of core outcome sets (an agreed minimum collection of outcomes to measure in research studies) in Cochrane systematic reviews: a review.

clinical trials general medicine (see internal medicine) statistics & research methods

Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
06 09 2020
Historique:
entrez: 8 9 2020
pubmed: 9 9 2020
medline: 15 5 2021
Statut: epublish

Résumé

A core outcome set (COS) is an agreed standardised minimum collection of outcomes that should be measured and reported in research in a specific area of health. Cochrane systematic reviews ('reviews') are rigorous reviews on health-related topics conducted under the auspices of Cochrane. This study examines the use of existing COS to inform the choice of outcomes in Cochrane systematic reviews ('reviews') and investigates the views of the coordinating editors of Cochrane Review Groups (CRGs) on this topic. A cohort of 100 recently published or updated Cochrane reviews were assessed for reference to a COS being used to inform the choice of outcomes for the review. Existing COS, published 2 or more years before the review publication, were then identified to assess how often a reviewer could have used a relevant COS if it was available. We asked 52 CRG coordinating editors about their involvement in COS development, how outcomes are selected for reviews in their CRG and their views of the advantages and challenges surrounding the standardisation of outcomes within their CRG. In the cohort of reviews from 2019, 40% (40/100) of reviewers noted problems due to outcome inconsistency across the included studies. In 7% (7/100) of reviews, a COS was referenced in relation to the choice of outcomes for the review. Relevant existing COS could be considered for a review update in 35% of the others (33/93). Most editors who responded (31/36, 86%) thought that COS should definitely or possibly be used to inform the choice of outcomes in a review. Systematic reviewers are continuing to note outcome heterogeneity but are starting to use COS to inform their reviews. There is potential for greater uptake of COS in Cochrane reviews.

Identifiants

pubmed: 32895272
pii: bmjopen-2019-036562
doi: 10.1136/bmjopen-2019-036562
pmc: PMC7476465
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

e036562

Subventions

Organisme : Medical Research Council
ID : G0901530
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/S014357/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/L004933/1-Q30
Pays : United Kingdom

Informations de copyright

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: PRW and MC are members of the COMET (Core Outcome Measures in Effectiveness Trials) Management Group. JJK and JS are members of the CS-COUSIN (Cochrane Skin—Core Outcome Set Initiative) methods group. The remaining authors declare no competing interests.

Références

PLoS One. 2018 Feb 13;13(2):e0190695
pubmed: 29438429
PLoS One. 2018 Dec 28;13(12):e0209869
pubmed: 30592741
BMC Med Res Methodol. 2020 Feb 11;20(1):30
pubmed: 32046643
PLoS Med. 2016 Oct 18;13(10):e1002148
pubmed: 27755541
J Am Acad Dermatol. 2019 Jul;81(1):297-305
pubmed: 30878565
PLoS One. 2019 Dec 12;14(12):e0225980
pubmed: 31830081
PLoS One. 2016 Jan 19;11(1):e0146444
pubmed: 26785121
Syst Rev. 2016 Jan 20;5:11
pubmed: 26792080
PLoS One. 2014 Jun 16;9(6):e99111
pubmed: 24932522
Trials. 2017 Jun 20;18(Suppl 3):280
pubmed: 28681707
PLoS One. 2016 Dec 14;11(12):e0168403
pubmed: 27973622
J Clin Epidemiol. 2017 Apr;84:85-94
pubmed: 28249722
Res Involv Engagem. 2016 Jun 7;2:21
pubmed: 29062521
Lancet. 2014 Jan 18;383(9913):267-76
pubmed: 24411647
JAMA Ophthalmol. 2017 Sep 1;135(9):933-940
pubmed: 28772305
PLoS Med. 2017 Nov 16;14(11):e1002447
pubmed: 29145404
PLoS One. 2019 Sep 13;14(9):e0222418
pubmed: 31518375
PLoS One. 2008;3(11):e3684
pubmed: 18997866
BMJ Open. 2017 Feb 27;7(2):e012545
pubmed: 28242767
Trials. 2013 Jan 22;14:21
pubmed: 23339751
BMJ. 2010 Feb 15;340:c365
pubmed: 20156912
Trials. 2019 Feb 11;20(1):116
pubmed: 30744706

Auteurs

Paula R Williamson (PR)

MRC North West Hub for Trials Methodology Research, University of Liverpool and member of Liverpool Health Partners, Liverpool, UK prw@liv.ac.uk.

Ricardo de Ávila Oliveira (R)

DECIR Faculdade de Medicina, Universidade Federal de Uberlândia, Uberlândia, Brazil.

Mike Clarke (M)

Northern Ireland Methodology Hub, Centre for Public Health, Queen's University Belfast, Belfast, UK.

Sarah L Gorst (SL)

MRC North West Hub for Trials Methodology Research, University of Liverpool and member of Liverpool Health Partners, Liverpool, UK.

Karen Hughes (K)

MRC North West Hub for Trials Methodology Research, University of Liverpool and member of Liverpool Health Partners, Liverpool, UK.

Jamie J Kirkham (JJ)

Centre for Biostatistics, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK.

Tianjing Li (T)

Department of Ophthalmology, University of Colorado Denver, Denver, Colorado, USA.

Ian J Saldanha (IJ)

Center for Evidence Synthesis in Health, Brown University School of Public Health, Providence, Rhode Island, USA.

Jochen Schmitt (J)

Center for Evidence-based Healthcare, Medizinische Fakultät, Technische Universität Dresden, Dresden, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH